Phase 2 Start
ARCT: Phase 2 Start: A Phase 2, Multicenter, Double-Blind, Randomized, Controlled Trial of the Safety and Immunogenicity
September 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 1, 2026
- Company
- Arcturus Therapeutics Holdings Inc. (ARCT)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: A Phase 2, Multicenter, Double-Blind, Randomized, Controlled Trial of the Safety and Immunogenicity
- Indication
- Hematopoietic and Lymphatic System Neoplasm